Intrathecal therapy for the management of cancer pain
- 89 Downloads
Inadequately managed cancer pain continues to be a significant problem despite increased awareness, improved knowledge and understanding of pain pathophysiology, and standardized treatment guidelines of this distressing and debilitating symptom complex. Small subsets of patients who are refractory to optimal medical management because of drug toxicity or unsatisfactory analgesia may be candidates for exteriorized or implantable intrathecal drug delivery systems. By delivering opioids and other agents directly to the central nervous system, intrathecal drug administration can offer superior pain relief with less toxicity at a fraction of the systemic dose. With adjuncts such as local anesthetics and clonidine, intrathecal therapy also allows for broader therapeutic options in the most difficult of cases. In general, intrathecal therapy is underused despite evidence of its efficacy, safety, and cost-effectiveness.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 4.Smith TJ, Staats PS, Deer T, et al.: Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 2002, 20:4040–4049. This important study compares, in a randomized and controlled manner, the outcomes of implanted drug delivery systems compared with conventional medical management. The findings in favor of IT drug delivery are discussed in the text.PubMedCrossRefGoogle Scholar
- 9.Bedder MD, Burchiel K, Larson A: Cost analysis of two implantable narcotic delivery systems. J Pain Symptom Manage 1991, 6:368–373. This small study looks at the economics of exteriorized versus implanted IT drug delivery systems, and finds that therapy duration greater than 3 months favors an implanted system.PubMedCrossRefGoogle Scholar
- 10.Smith TJ, Coyne PJ, Staats PS, et al.: An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM). Ann Oncol 2005, 16:825–833.PubMedCrossRefGoogle Scholar
- 11.Stearns L, Boortz-Marx R, Du Pen S, et al.: Intrathecal drug delivery for the management of cancer pain: a multidisciplinary consensus of best clinical practices. J Support Oncol 2005, 3:399–408. These consensus guidelines offer a standardized approach to IT prescribing in the cancer patient, and also contain a great deal of very useful information regarding the practical management of implanted IT pumps.PubMedGoogle Scholar